"As far as up-and-coming drugs, California-based MannKind
Corporation (Nasdaq:MNKD) is in late-stage development
of AFREEZA®, a novel, fast-acting mealtime insulin
therapy for the treatment of adults with Type 1 and Type
2 diabetes mellitus for the control of hyperglycemia.
MannKind has developed AFREEZA® as a combination
drug/device consisting of the Company’s proprietary
Technosphere® particles onto which insulin molecules are
loaded. The particles are then aerosolized and inhaled
deep into the lung using MannKind’s AFREEZA® inhaler.
The Technosphere® Technology Platform was developed by
MannKind as a potentially superior and easy to use drug
delivery system that mimics the pharmacokinetics of
intra-arterial administration. After rejections from the
FDA in 2010 and again in 2011, MannKind is conducting
Phase 3 clinical trials per guidance from the Food and
Drug Administration as issued in a second complete
response letter in from the FDA in January 2011 and
End-of-Review meetings in May of 2011.

MannKind is also developing MKC253, a formulation of
GLP-1 (glucagon-like peptide) on Technosphere® particles
that is delivered using its inhaler. MKC253 is in Phase
1 clinical trials for the treatment of type 2 diabetes."

http://www.pennymotion.com/penny-stock-newsletters/companies-looking-towards-future-revenue-with-new-diabetes-therapies/